Sacher AI logo
Book a call

GLP-1 and obesity care

GLP-1 medicines work in trials. Real-world results depend on behaviour.

In a study of more than 125,000 US adults with overweight or obesity, just over half (54%) stopped within a year. Many of the reasons are behavioural: how people cope with side effects, unrealistic expectations, waning motivation, and the everyday barriers that make lasting change hard. That is the part we work on.

Source: Rodriguez PJ et al., JAMA Network Open, 2025.

Book a discovery callHow we work with you

Who we work with

Two kinds of team, and where each usually starts.

GLP-1 and obesity care providers

You run a telehealth service, clinic, pharmacy or weight management programme. You want more patients to stay on treatment, better support between appointments, or a patient-facing AI assistant that is safe to use.

  • Design and deliver →

    Turn an idea into a tested prototype or MVP, working alongside your own team. We cover the technical planning, product, design, behavioural logic and conversation design. Your team keeps the production build.

  • Test and prove →

    Show that your AI is safe and that it works. We test it with PromptSafe, evaluate it independently using the FAST framework, and can take the research through to peer-reviewed publication.

Organisations building around GLP-1 treatment

You work in life sciences, medtech or digital health, and you need to decide whether a new product or service is worth the investment before you build it.

  • Decide →

    Find out whether an idea is worth building before you commit the budget. A fixed fee Evidence Phase of 8 to 12 weeks tests the idea using the Before You Build Method, and ends with a clear recommendation to go ahead, rework or stop.

Across the whole journey

Support that adapts from the first dose to long-term maintenance.

  1. 01

    Starting treatment

    Onboarding, expectations, and the first doses, when confidence is lowest.

  2. 02

    The first weeks

    Reassurance and practical routines while people adjust, with any clinical questions passed to their clinical team.

  3. 03

    Pauses and dips

    Missed doses, and the weeks when life gets in the way.

  4. 04

    Reaching a goal

    Recognising progress without letting the habits behind it slip.

  5. 05

    Long-term maintenance

    Whether someone stays on a maintenance dose, steps down, or stops.

Behavioural phenotyping

Support designed around how people actually think, feel, and act.

Two people on the same medication can need completely different support. One sets impossibly high standards and gives up after a single slip. Another eats to manage stress. Another is pulled off course by the people around them, or by a schedule with no room for self-care.

Behavioural phenotyping identifies the psychological and behavioural drivers behind each person's eating, activity, and adherence, and turns them into tailored, evidence-based support, delivered in the tone, framing, and intensity that fit the individual.

Perfectionism and all-or-nothing thinking

Helps people treat a slip as a normal part of change and get back on track, so one bad day does not end the whole effort.

Emotional eating

Helps people spot what sets off their eating, and tell physical hunger apart from eating to cope with stress or low mood.

Social and environmental pressure

Helps people plan what to say and do in the social situations that most often throw them off course.

A pull towards quick rewards over slow progress

Sets small, achievable goals with non-food rewards, so steady progress feels worth the effort.

Unrealistic expectations

Explains honestly what progress usually looks like and how long it takes, so disappointment does not lead people to stop early.

Time and life pressures

Suggests quick, realistic actions and simple ways to manage stress during busy or disrupted weeks.

Low confidence and self-efficacy

Gives clear next steps and recognises progress, so people come to believe they can change.

Scepticism about behaviour change

Takes people's doubts seriously and answers them respectfully, with specific evidence they can trust.

Fear of failure

Starts with small steps and celebrates progress beyond the scale, so trying feels less risky.

Where the line sits

Behavioural support, with clinical decisions left to clinicians.

  • Support, not clinical decisions

    Our behavioural AI supports people between appointments. Clinical decisions, such as whether to stop, pause or switch treatment, stay with the person's own clinician. We design that boundary in from the start.

Case studies

Our work in GLP-1 and obesity care.

See all case studies →

Decide

Twenty AI ideas, narrowed to the six worth doing

An international GLP-1 care provider had heavy support demand and was losing patients early. We helped it narrow more than twenty AI ideas to the six worth building, with a phased roadmap.

Read the case study →

Design and deliver

Personalised AI health coaching deployed across obesity care

For Allurion, our team designed the behavioural architecture of personalised AI health coaches for obesity and GLP-1 care, deployed internationally and serving very large patient populations.

Read the case study →

Design and deliver

Safe, personalised patient-facing AI for people on weight-loss medication

Embedded within Numan's team from the very beginning, Sacher AI helped create an AI Health Assistant for patients on anti-obesity medications, alongside Aegis, a monitoring, safety, and escalation system.

Read the case study →

GLP-1 Digest podcast, episode 8

Can AI stop GLP-1 patients from churning?

Dr Paul Sacher with Dr Ashwin Sharma on how direct-to-consumer platforms keep patients without lowering prices.

Open the episode on GLP-1 Digest ↗

Next step

Working on GLP-1 or obesity care?

Book a discovery call. We will work out whether there is a fit and what a sensible first step looks like.

Book a discovery call